|Name of Trial||Study Objectives|
|CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass||Nonrandomized trial to determine the safety and efficacy of the Levitronix CentriMag ventricular assist system in hemodynamically unstable patients with cardiac dysfunction who cannot be weaned from cardiopulmonary bypass for up to 30 days|
|EXCOR Pediatric Ventricular Assist Device (VAD) as a Bridge-to-Cardiac Transplantation||Prospective multicenter, historical control, single-arm study to examine the safety and potential benefit of the Berlin Heart EXCOR Pediatric VAD as a bridge to cardiac transplantation in children|
|HARPS (Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure)||Nonrandomized, open-label, multicenter trial to assess the percentage of HeartMate XVE patients who, when treated with clenbuterol in conjunction with conventional oral heart failure medications, recover adequate cardiac function to be removed from VAD support and not require heart transplantation|
|Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure||Open-label, nonrandomized study to establish the safety and effectiveness of the HeartWare LVAD system in refractory heart failure patients listed for cardiac transplantation|
|Jarvik 2000 Heart as a Bridge to Cardiac Transplantation—Pivotal Trial||Phase II and III study to ascertain the safety and effectiveness of the Jarvik 2000 Heart as a bridge to heart transplantation in end-stage heart failure patients who are approved transplantation candidates|
|Evaluation of Myocardial Improvement in Patients Supported by Ventricular Assist Device Under Optimal Pharmacological Therapy||Randomized, single-blind trial designed to assess the recovery of myocardial function in VAD bridge to transplantation patients treated with either high- or standard-dose pharmacologic therapy|
|Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy||Prospective, multicenter, noninferiority trial evaluating the efficacy and safety of the HeartMate II in ineligible transplantation patients with NYHA functional class III or IV heart failure. Patients will be randomized in a 2-to-1 basis to the HeartMate II and the HeartMate XVE|
|VentrAssist LVAD for the Treatment of Advanced Heart Failure||Multicenter, prospective, randomized, controlled clinical trial to explore the use of the VentrAssist LVAD in patients with chronic stage D heart failure who are ineligible for a heart transplantation|
|VentrAssist LVAD as a Bridge to Cardiac Transplantation—Feasibility Trial||Nonrandomized, historical control phase II and III clinical trials of the VentrAssist LVAD, a centrifugal flow pump, to determine the safety and feasibility in patients who require an LVAD as a bridge to cardiac transplantation|
This table lists current ongoing trials of VADs. Final results of these clinical investigations have not yet been published.
NYHA = New York Heart Association; other abbreviations as in Table 3.